Prognostic significance of platelet-to-lymphocyte ratio in urothelial carcinoma patients: a meta-analysis

Yuhai Bao, Yin Wang, Xiaodong Li, Mingjun Pan, Hongze Zhang, Zegen Cheng, Xueyi WangCancer 2019 · DOI

TL;DR

This meta-analysis of 15 studies involving over 5,000 patients found that a high pre-treatment platelet-to-lymphocyte ratio (PLR) is a significant predictor of poorer progression-free survival (PFS) and disease-free survival (DFS) in patients with urothelial carcinoma (UC). This simple, non-invasive blood marker could aid in clinical decision-making and patient prognostication.

What Problem Does This Paper Address?

Urothelial carcinoma (UC), particularly upper tract urothelial carcinoma (UTUC), is a significant health concern. While treatments exist, predicting patient outcomes and identifying reliable prognostic markers remains a challenge. Existing biomarkers have shown limitations in their prognostic efficiency. The paper addresses the need for accessible and effective prognostic indicators to guide treatment and improve patient management. Specifically, it investigates the role of the platelet-to-lymphocyte ratio (PLR), a marker reflecting systemic inflammation, which has shown promise in other cancers but has yielded inconsistent findings in UC.

Methods

This study employed a meta-analysis approach to systematically review and synthesize data from existing research. The researchers searched major databases (PubMed, Embase, Web of Science, Cochrane Library) for relevant studies published between 2015 and 2019. They included studies that met specific criteria, such as pathologically confirmed UC, evaluation of PLR's correlation with survival outcomes (overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and cancer-specific survival (CSS)), and defined PLR cut-off values. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to summarize survival correlations, while odds ratios (ORs) with 95% CIs were used for clinicopathological factors. Heterogeneity was assessed using Cochran's Q test and Higgins' I-squared statistics, with random-effects models used for significant heterogeneity and fixed-effects models otherwise. Publication bias was evaluated using Begg's funnel plots and Egger's linear regression tests.

Datasets

The study is a meta-analysis, meaning it synthesizes data from existing published studies. It analyzed data from 15 cohort studies published between 2015 and 2019, involving a total of 5,354 patients diagnosed with urothelial carcinoma. These studies were conducted across six countries: China (5 studies), Korea (4 studies), Japan (3 studies), Austria (1 study), Poland (1 study), and Turkey (1 study). No new datasets were introduced.

Key Insights and Ideas

  • PLR as a readily accessible prognosticator: The study highlights that PLR, a simple blood test, can provide valuable prognostic information for UC patients, potentially guiding clinical decisions without the need for invasive procedures.
  • Differential impact on survival outcomes: While PLR showed a significant association with poorer PFS and DFS, it did not demonstrate a significant correlation with overall survival (OS) or cancer-specific survival (CSS) in the overall analysis. This suggests PLR might be more sensitive to factors influencing disease progression and recurrence rather than long-term mortality in the general UC population.
  • Inflammation's role in UC progression: The findings reinforce the growing understanding of the systemic inflammatory response's crucial role in cancer development and progression, with PLR serving as a hematological indicator of this response.
  • Association with specific clinical factors: The study identified that elevated PLR is significantly associated with older patient age (>65 years) and hypertension, suggesting these factors might influence the inflammatory state reflected by PLR in UC patients.

Key Results

  • PFS and DFS: A high PLR was significantly correlated with poorer PFS (HR = 1.81, 95% CI 1.28-2.56, p=0.001) and DFS (HR = 1.69, 95% CI 1.31-2.16, p<0.001).
  • OS and CSS: No significant association was found between high PLR and poorer OS (HR = 1.23, 95% CI 0.95-1.59, p=0.124) or CSS (HR = 1.000, 95% CI 0.998–1.002, p=0.919).
  • Clinicopathological factors: Elevated PLR was associated with patient age > 65 years (OR = 1.72, 95% CI 1.25-2.38, p=0.001) and hypertension (OR = 1.48, 95% CI 1.01–2.18, p=0.046). No significant association was observed with sex or diabetes.
  • Subgroup analysis: The prognostic value of PLR for DFS and PFS was not influenced by tumor type (UTUC vs. BC).

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective nature: All included studies were retrospective, which may introduce selection bias.
  • Limited data on clinical factors: Only four studies provided data on the association between PLR and clinicopathological factors, limiting the scope of subgroup analyses for these correlations.
  • Lack of individual patient data: The meta-analysis used pooled data, preventing detailed individual-level analysis.
  • Variability in PLR normalization: Blood counts can vary at different sites, making it challenging to normalize PLR values consistently across studies.

The authors suggest that additional large-scale prospective studies are warranted to confirm these findings and further elucidate the prognostic role of PLR in UC. They also emphasize that while PLR is a useful indicator, it should be considered alongside other clinicopathological factors for comprehensive patient prognostication.

Summary updated

Abstract

Our results demonstrated a significant correlation between elevated PLR and poor prognosis in UC. The prognostic role of PLR may help guide the management and prognostication of UC patients.
BibTeX
@inproceedings{bao2019prognostic,
  author = {Yuhai Bao and Yin Wang and Xiaodong Li and Mingjun Pan and Hongze Zhang and Zegen Cheng and Xueyi Wang},
  title = {{Prognostic significance of platelet-to-lymphocyte ratio in urothelial carcinoma patients: a meta-analysis}},
  booktitle = {Cancer},
  year = {2019},
  doi = {10.1186/s12935-019-1032-6},
}
Figure